Please write in the missing info below……
Can you help fill in the blanks??
The Early Cancer Detection Consortium, building the evidence base by mapping of the UK Cancer Sample Banks Becky Whiteman 1&2, Michael Messenger3, Ian Cree2&1
on behalf of the Early Cancer Detection Consortium (ECDC)
Introduction
1-Centre for Technology Enabled Health Research, Coventry University, Coventry , UK. 2-University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. 3-NIHR Diagnostic Evidence Co-Operative Leeds, Leeds, UK.
Methods
In 2012 a number of UK universities established an Early Cancer Detection (ECD) Consortium to identify, validate and implement a new generic blood test for asymptomatic cancer screening in general practice (see figure 1). The introduction of ECDC blood tests should improve early detection across all cancer types, while extending significantly the population of GP patients who are identified as at risk. As part of the underlying evidence base for the programme, and to understand the availability of retrospective blood samples for potential use within the research, the Consortium undertook a mapping review of the UK Cancer Sample Banks.
To inform the development of new blood tests for generic early cancer detection, retrospective blood samples have been considered for use during the analytical & clinical validation phases. As part of a scoping process and building upon expert knowledge from Consortium members, Cancer Research UK and UK pathology experts a list of available UK blood and associated tumour information sample banks was developed. The list was built upon through searching of publically available UK cancer study information, and biobank information held within academic information freely available on the web. A proforma was developed to collect detailed information including number of samples held, tumour type, cases numbers and stage, controls, sample type (serum/plasma/whole blood), volume of sample held, number of aliquots and contact details for access to the samples.
Figure 1: The conceptual model of the generic blood based screening test
Results To date fourteen blood based sample banks have been identified, with more being identified on a regular basis. Full details of some of the sample banks have yet to be identified, locating the holders of the detailed information has often been difficult to establish and to subsequently gain detailed information. Figure 2 outline’s the details of UK blood based Cancer Sample Banks identified by the Consortium, thought potentially to be of benefit for consideration as part of the scoping process.
Figure 2: Identified UK blood based cancer sample banks Southampton NCRN MRC UKLS UK Lung Breast Cancer PROMIS Cancer Screening
ReSoLuCENT ACP
Location
Sheffield
Manchester Southampton UCH London
Tumour type
Lung
Breast
Breast
Prostate
Lung
Prostate
Bladder
circa 600
~1200
100 + NNN DCIS
714
42
~1500
Stage 1/2 31
-
-
-
Stage 3
-
-
207
Stockport
Manchester London / Abcodia
Renal
Renal
Lung
UGI
Assorted
Ovarian
~1500
>500
706**
-
Barrett's esophagus
-
-
-
-
298 clear cell -
-
-
-
-
-
183 clear cells -
-
-
-
-
-
-
esophagitis (severe)
-
-
-
-
Serum
-
-
-
-
-
-
-
-
~1200
600
-
1958
~1500
-
-
plasma, whole blood serum lymphocytes,
serum, plasma, whole blood
plasma
whole blood -
Aliquot volume
~1ml plasma, ~2-5ml ~300ul lymphocytes
-
~2ml
-
~5ml
-
~350uL
~350uL
-
-
-
Number of aliquots
~3 aliquots plasma, ~1 aliquot lymphocytes
~2 aliquots
-
~4 aliquots serum, 9ml whole = DNA, 2.5ml = RNA
2 aliquots
-
~10 aliquots per matrix /sample/ timepoint
~10 aliquots per matrix /sample/ timepoint
-
-
A Cox
K Muir
R Cutress
H Ahmed
K Muir
M Messenger
M Messenger
J Jankowski
Controls
Circa 400
Sample type
Contact info
D Baldwin
NSHLG
Nottingham Coventry
-
388
UKCTOCs
Leeds
-
Stage 4
Volume
Nottingham Manchester Birmingham Leeds
CHOPIN / UK ASPECT Biobank
Mainly DCIS
Cases
Total
UKGPCS
Birmingham Leeds MD Leeds NIHR ECLS Bladder Research Biomarkers Scotland Tissue Bank Research Cancer Tissue Bank
Sample Bank
Serum, EDTA Plasma, Buffy coat
?N James
stage III and IV
-
199 healthy volunteers Serum, EDTA Plasma, Buffy coat
?F Sullivan
UK Biobank
**706 = (clear cell (68%), papillary (8%), chromophobe (6%), as well as benigns, unclassified and translocation tumours.)
Conclusions The mapping of UK cancer sample banks will be a valuable tool for UK researchers seeking potential sources of retrospective blood samples for future cancer research. The authors recognise that the current mapping is likely to still be missing some available blood and associated tumour information sample banks and will continue to build upon this initial list. If you know of other cancer sample banks containing blood with associated tumour information within the UK, which could be used for cancer research purposes, please contact one of the authors.
Acknowledgements This work was conducted on behalf of the Early Cancer Detection Consortium, within the programme of work for work packages 1 & 2. The Early Cancer Detection Consortium is funded by Cancer Research UK, grant number: C50028/A18554.
Contact: Becky Whiteman, Clinical Research Fellow – Centre for Technology Enabled Health Research, Coventry University, Priory Street, Coventry, CV1 5FB. email
[email protected] twitter @becky_whiteman
500,000 await detailed results
Hodgkins Lymphoma -
-
I Jacobs / Abcodia
?R Houlston
